Status epilepticus

EISAI SUBMITS MARKETING AUTHORIZATION APPLICATION FOR LECANEMAB AS TREATMENT FOR EARLY ALZHEIMER'S DISEASE IN EUROPE

Retrieved on: 
Tuesday, January 10, 2023
Cerebral edema, Intracerebral hemorrhage, Anticoagulant, Arthralgia, Aspirin, Stroke, MRI, Dizziness, Cerebral contusion, Seizure, Hypotension, Effectiveness, Status epilepticus, Diarrhea, Clopidogrel, Alzheimer's disease, Aneurysm, Risk, Vomiting, ARIA, Chills, AND, Disease, Nausea, Patient, Intracranial hemorrhage, Vascular malformation, Cough, Paracetamol, Hypertension, Focal neurologic signs, Headache, Observation, Incidence, Tissue plasminogen activator, Confusion, Siderosis, Fever, Medical device, Pharmaceutical industry, Medical imaging, Clothing

Treatment with LEQEMBI should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials.

Key Points: 
  • Treatment with LEQEMBI should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials.
  • There are no safety or effectiveness data on initiating treatment at earlier or later stages of the disease than were studied.
  • Depending on ARIA severity, use clinical judgment in considering whether to continue dosing, temporarily discontinue treatment, or permanently discontinue LEQEMBI.
  • In Study 1, 15% of LEQEMBI-treated patients, compared to 6% of placebo-treated patients, stopped study treatment because of an adverse reaction.

PharmaTher Announces FDA Orphan Drug Designation Granted to Ketamine for Prevention of Ischemia-Reperfusion Injury from Organ Transplantation

Retrieved on: 
Thursday, December 15, 2022
Complex regional pain syndrome, Status epilepticus, Liver, Neurological disorder, Emergency, Life expectancy, Diagnosis, Disorder, Quality of life, Mortality, Reperfusion, Incidence, Ischemia, Kidney, Food, Marketing, FDA, Ischemia-reperfusion injury of the appendicular musculoskeletal system, Organ transplantation, Neuromuscular disease, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Seizure, Amyotrophic lateral sclerosis, Heart, Ischemic preconditioning, CSE, IL-6, Disease, Orphan drug, Orphan Drug Act of 1983, Transplant, Lung, OTCQB, IRI, Red blood cell, Injury, Rett syndrome, Patient, Mental health, Pharmaceutical industry, Dentistry, Vaccine, Ketamine

TORONTO, Dec. 15, 2022 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a leader in specialty ketamine pharmaceuticals, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for ketamine in the prevention of ischemia-reperfusion injury from organ transplantation.

Key Points: 
  • TORONTO, Dec. 15, 2022 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a leader in specialty ketamine pharmaceuticals, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for ketamine in the prevention of ischemia-reperfusion injury from organ transplantation.
  • Fabio Chianelli, CEO of PharmaTher, commented: “This is our fourth orphan drug designation granted by the FDA for ketamine.
  • Organ Procurement and Transplantation Network, there were 41,355 solid organ transplantations in 2021, and thus far in 2022, there has been 39,241 solid organ transplantation with approximately 105,000 patients waiting for solid organ transplants in the United States.
  • The Orphan Drug Act grants special status to a drug or biological product to treat a rare disease or condition upon request of a sponsor.

SciSparc Enters Into Non-Binding Letter of Intent to Sell a 50% interest in its Subsidiary that Owns an Amazon Top Seller Brand

Retrieved on: 
Wednesday, December 14, 2022
Autism, Status epilepticus, Annual report, TEL, Sale, THC, ASIN, Central nervous system, Tourette syndrome, Pain, Hair, Candy, Agitation, Beauty, Alzheimer's disease, Jeff Brandes, CBD, Amazon (company), Pharmaceutical industry, Amazon

The sale is subject to the negotiation and the execution of a binding definitive agreement.

Key Points: 
  • The sale is subject to the negotiation and the execution of a binding definitive agreement.
  • There can be no assurances that the sale will proceed, nor can there be any assurance as to the final definitive terms thereof, including form of consideration.
  • SciSparc Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists.
  • In total, the brand has over 40,000 product reviews, most of which are 4 and 5-star reviews.

SciSparc Announces Positive Study Results with SCI-210, a Cannabidiol-Based Treatment for Epilepsy

Retrieved on: 
Wednesday, December 7, 2022
PEA, Status epilepticus, Autism, Mortality, Annual report, Animal, Research, Sheba Medical Center, SE, Health care, THC, Seizure, Tourette syndrome, Central nervous system, Pain, Epilepsy, Doctor of Philosophy, Agitation, Calibration, Alzheimer's disease, CBD, Patient, Pharmaceutical industry, Palmitoylethanolamide, Cannabidiol

Tel-Aviv, Dec. 07, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the “Company” or “SciSparc”), today announced positive results from its study of SCI-210 on Status Epilepticus ("SE"), conducted at The Sheba Fund for Health Services and Research at Chaim Sheba Medical Center, which reaffirm the potential of its proprietary combination products to have a positive effect while minimizing adverse side effects. The Company's proprietary SCI-210 platform combines Palmitoylethanolamide (“PEA”) with Cannabidiol (“CBD”).

Key Points: 
  • The non-clinical trial objective was to study the potential therapeutic effects of SCI-210 on SE and on neuro-biochemical markers for neurological cognitive sequelae.
  • A pilocarpine SE-induced mice (C57BL/6 male) model to study SCI-210’s effects on seizure severity and mortality was used.
  • The results indicated differences in mortality rate as well as seizure rates over time.
  • There is limited pharmaceutical treatment available for treating epilepsy, as about one in three patients have drug- resistance against epilepsy," said Adi Zuloff-Shani, PhD, Chief Technology Officer of SciSparc.

SciSparc Regains Compliance with Nasdaq Minimum Closing Bid Price Rule

Retrieved on: 
Tuesday, November 29, 2022
Agitation, Central nervous system, Pain, THC, Status epilepticus, Autism, CBD, Tourette syndrome, Alzheimer's disease, Pharmaceutical industry

Tel-Aviv, Nov. 29, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the Company or SciSparc), reported the receipt of a formal notification from The Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained compliance with Listing Rule 5550(a)(2), which requires the Company's ordinary shares to maintain a minimum bid price of $1.00 per share.

Key Points: 
  • Tel-Aviv, Nov. 29, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the Company or SciSparc), reported the receipt of a formal notification from The Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained compliance with Listing Rule 5550(a)(2), which requires the Company's ordinary shares to maintain a minimum bid price of $1.00 per share.
  • The Nasdaq staff made this determination of compliance after the closing bid price of the Company's ordinary shares was at $1.00 per share or greater for the prior 10 consecutive business days.
  • Accordingly, the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2) and Nasdaq considers the prior bid price deficiency matter now closed.
  • SciSparc Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists.

SK life science To Present Latest XCOPRI® (cenobamate tablets) CV Data at the American Epilepsy Society 2022 Annual Meeting

Retrieved on: 
Monday, November 28, 2022
Ignis, Mouth, Skin, Bleeding, Rash, NOT, Falling, United Kingdom, SK, Neurological disorder, Ideation, SK Group, Epilepsy, Risk, Therapy, Fever, Bruise, Allergy, GABAA, Greater, Restless, Brain, Semiconductor, SUDEP, Dizziness, Heart, Infection, Union, Ono Pharmaceutical, Vitamin, Patient, Fatigue, Somnolence, Anxiety, Nervous system, ASMS, Seizure, Irritability, ASM, FDA, Tongue, Suicide, Cenobamate, History, Drowning, Work, Face, Central nervous system disease, Depression, News, Behavior, Research, Walking, Medication, Pregnancy, Safety, Liver, Weakness, Headache, CV, Accident, Central nervous system, Thought, CNS, Blood, Palpitations, Status epilepticus, Insomnia, Mania, Death, Investment, Pharmaceutical industry, Liquor, Birth control, Fine chemical

PARAMUS, N.J., Nov. 28, 2022 /PRNewswire/ -- SK Life Science, Inc., a subsidiary of SK Biopharmaceuticals Co., Ltd., an innovative global pharmaceutical company focused on developing treatments for central nervous system (CNS) disorders, will present data on XCOPRI® (cenobamate tablets) CV, at the American Epilepsy Society (AES) Annual Meeting, to be held December 2 – 6, 2022 in Nashville, Tennessee.

Key Points: 
  • Cenobamateis an anti-seizure medication (ASM) discovered and developed by SK Biopharmaceuticals and SK life science.
  • DO NOT TAKE XCOPRI IF YOU:
    Are allergic to cenobamate or any of the other ingredients in XCOPRI.
  • Do not stop taking XCOPRI without first talking to your healthcare provider.Stopping XCOPRI suddenly can cause serious problems.
  • Both SK Biopharmaceuticals and SK life science are part of SK Group, one of the largest conglomerates in Korea.

EQS-News: Can This Company’s Positive Results For Psychedelic Combination Treatment Provide Hope For Alcohol And Cocaine Addiction Problems?

Retrieved on: 
Sunday, November 27, 2022
California Rehabilitation Center, Growth, Heart, Spleen, United Nations Office on Drugs and Crime, THC, WHO, Drug overdose, Tourette syndrome, Hand, Agitation, SUD, Pain, Safety, Brain, Advertising, Chronic pain, Research report, United Nations, PEA, Cocaine, Autism, World Drug Report, National Center for Telehealth & Technology, Rat, Pancreas, Inflammation, Death, Addiction, AMPH, World Health Organization, CNS, Disease, UNODC, Status epilepticus, Crave, CBD, Alzheimer's disease, Disability-adjusted life year, Drug, Research, Therapy, Thyroid, Viatris, CSE, Substance abuse, Animal, Liver, Probability, MEAI, Pharmaceutical industry, Crime

Can This Companys Positive Results For Psychedelic Combination Treatment Provide Hope For Alcohol And Cocaine Addiction Problems?

Key Points: 
  • Can This Companys Positive Results For Psychedelic Combination Treatment Provide Hope For Alcohol And Cocaine Addiction Problems?
  • Whether its a problem with opioids, alcohol, cocaine, or even using pain meds, an unchecked addiction can be fatal.
  • Take alcohol abuse, for example; the World Health Organization (WHO) estimates that three million deaths yearly result from the harmful use of alcohol.
  • On Aug. 24, the company announced additional positive preclinical results of its psychedelic-based pharma collaboration for treating cocaine addiction using MEAI.

Jeffs' Brands Enters Into Letter of Intent with a Pharmaceutical Company to Establish a Joint Venture to Develop and Market a New Product Line

Retrieved on: 
Tuesday, November 15, 2022
Marketing, FBA, Jeff Brandes, THC, Agitation, Pain, Amazon Marketplace, Autism, Register, Status epilepticus, James v Redcats (Brands) Ltd, Candy, LOI, Letter, CBD, Alzheimer's disease, Health, Form, FBM, Hair, Documentation, Beauty, ASIN, JV, Public expenditure, Tourette syndrome, Dietary supplement, Amazon

Tel Aviv, Israel, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Jeffs' Brands Ltd (the “Company”) (Nasdaq: JFBR), a data-driven e-commerce company operating on the Amazon Marketplace, today announced it has entered into a letter of intent ("LOI") with SciSparc Ltd. ("SciSparc") (Nasdaq: SPRC), a specialty pharmaceutical and food supplements company, to establish a joint venture ("JV") for the development of a new food supplements product line and its online marketing. 

Key Points: 
  • Upon entry into definitive documentation, Jeffs' Brands will be responsible for the online marketing of the products developed by SciSparc as part of the JV.
  • Mr. Oz Adler, the Chairman of the Company, is the Chief Executive Officer of SciSparc and a director of the Company is the Chairman of SciSparc.
  • Jeffs' Brands Ltd is transforming the world of e-commerce by creating and acquiring products and turning them into market leaders, tapping into vast, unrealized growth potential.
  • For more information on Jeffs Brands Ltd, visit https://jeffsbrands.com
    SciSparc Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists.

SciSparc Enters Into Letter of Intent with an E-commerce Company to Establish a Joint Venture to Market and Develop a New Product Line

Retrieved on: 
Tuesday, November 15, 2022
FBA, Jeff Brand, THC, Agitation, Pain, TEL, Amazon Marketplace, Autism, Annual report, Central nervous system, Status epilepticus, James v Redcats (Brands) Ltd, Candy, LOI, Letter, CBD, Risk, Alzheimer's disease, Hair, Documentation, Beauty, ASIN, JV, Tourette syndrome, Pharmaceutical industry, Amazon

TEL AVIV, Israel, Nov. 15, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the “Company” or “SciSparc”), today announced it has entered into a letter of intent ("LOI") with Jeffs' Brands Ltd ("Jeffs' Brands") (Nasdaq: JFBR), a data-driven e-commerce company operating on the Amazon Marketplace, to establish a joint venture ("JV") for the development of a new food supplements product line and its online marketing. 

Key Points: 
  • The LOI contemplates that the two companies will form a JV in which they each own 50%.
  • Upon entry into definitive documentation, SciSparc will be responsible for the development of the new product line that will be marketed by Jeffs' Brands as part of the JV.
  • Mr. Oz Adler, the Chief Executive Officer of the Company, is the Chairman of Jeffs Brands and the Chairman of the Company is a director of Jeffs Brands.
  • SciSparc Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists.

Marinus Pharmaceuticals Announces Collaboration with Tenacia Biotechnology for Ganaxolone Development and Commercialization in China

Retrieved on: 
Thursday, November 17, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, Medication, Clinical trial, Brain, Epilepsy, Ganaxolone, CDKL5, Eugnosta tenacia, Drug development, CNS, Security (finance), Marinus, IV, Therapy, Central nervous system, COVID-19, CV, Seizure, GABAA, Status epilepticus, Patient, Pharmaceutical industry

Tenacia is expected to drive the development and commercialization of ganaxolone in China across our current focus areas of CDKL5 deficiency disorder, tuberous sclerosis complex and status epilepticus, and to potentially play a key role in the development of a next generation ganaxolone formulation.

Key Points: 
  • Tenacia is expected to drive the development and commercialization of ganaxolone in China across our current focus areas of CDKL5 deficiency disorder, tuberous sclerosis complex and status epilepticus, and to potentially play a key role in the development of a next generation ganaxolone formulation.
  • Partnering with Marinus to develop and commercialize ganaxolone in China positions us well to quickly become a pioneer in the development of treatments that target significant unmet medical needs for epilepsy patients, said Dr. Xiaoxiang Chen, Chief Executive Officer of Tenacia Biotechnology.
  • We look forward to collaborating closely with Marinus while exploring the full potential of ganaxolone.
  • Based in China, Tenacia Biotechnology (Shanghai) Co., Ltd. is an emerging biotech company focused on the development of innovative treatments for central nervous system (CNS) disorders.